BiotechTube
OMEICOS Therapeutics

OMEICOS Therapeutics

Berlin, Germany· Est.
omeicos.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

OMEICOS Therapeutics is a private, clinical-stage biotech leveraging proprietary science in omega-3 fatty acid metabolism to develop novel small molecules. Its lead asset, OMT-28, targets inflammation and mitochondrial dysfunction and has successfully completed a Phase 2 trial in atrial fibrillation, showing safety and positive biomarker modulation. The company is now advancing OMT-28 into a Phase 2 proof-of-concept study in primary mitochondrial diseases and planning a study in coronary artery disease, positioning it in large, underserved therapeutic markets.

CardiovascularInflammatory DiseasesMitochondrial Diseases

Technology Platform

Proprietary small molecule platform targeting a natural cell-protective pathway involved in omega-3 fatty acid metabolism, designed to address both inflammation and mitochondrial dysfunction.

Funding History

2
Series AUndisclosed
SeedUndisclosed

Opportunities

OMT-28 addresses massive markets in cardiovascular disease (AF, CAD) with high unmet need for anti-inflammatory therapies, and the rare disease space (PMD) which lacks any approved disease-modifying treatments, allowing for potential premium pricing.
The dual mechanism targeting inflammation and mitochondrial dysfunction could provide a differentiated and broad therapeutic profile across multiple indications.

Risk Factors

The primary risk is clinical failure, as positive biomarker data from the AF trial may not translate to improved hard clinical outcomes in ongoing and future studies.
The company also faces significant financing risk as a private, pre-revenue entity funding multiple Phase 2 trials, and competitive risk from other companies targeting inflammation and mitochondrial function in large therapeutic areas.

Competitive Landscape

In cardiovascular inflammation, OMT-28 would compete with other novel anti-inflammatory agents (e.g., targeting IL-1β, IL-6) being investigated for residual cardiovascular risk. In mitochondrial diseases, the landscape is sparse with no approved therapies, but several biotechs are developing gene therapies, small molecules, and cofactor supplements. OMEICOS's differentiation lies in its unique pathway and dual-action approach.

More companies in Small Molecule Drugs →More companies in Germany →